secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2023-07-19T23:59:59+00:00
Accession:  0001104659-23-082362
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharmaceuticals CEO Dr. Brian Varnum departs; severance includes 12-month salary continuation
--------------------------------------------------------------------------------

- Dr. Brian Varnum's employment terminated July 10, 2023; separation agreement signed July 14, 2023.
- Severance includes base salary continuation for 12 months and COBRA premium payments for up to 12 months.
- Unvested options that would have vested within one year will vest on first anniversary; exercise extended to Sept 30, 2024.
- Agreement includes non-disparagement, confidentiality, and reaffirmation of existing restrictive covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465923082362/0001104659-23-082362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465923082362/tm2321631d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-082362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer